December 2024
1. GENDOLLA A, Brown JD, Mercadante AR, Drakeley S, et al
   The incremental burden and healthcare resource utilization among people with migraine in Europe: Insights from the 2020 European National Health and Wellness Survey.
   Cephalalgia. 2024;44:3331024241276415.
   

   >> Share

   
   November 2024
2. BURGALASSI A, Romozzi M, Vigani G, De Icco R, et al
   Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study.
   Cephalalgia. 2024;44:3331024241273968.
   

   >> Share

   
   
3. SACCO S, De Santis F, Onofri A, Rosignoli C, et al
   A call for academic pragmatic clinical trials to address open questions in migraine prevention.
   Cephalalgia. 2024;44:3331024241291574.
   

   >> Share

   
   
4. CLOET F, Gueyraud G, Lerebours F, Munio M, et al
   Stroke due to small-vessel disease and migraine: A case-control study of a young adult with ischemic stroke population.
   Cephalalgia. 2024;44:3331024241282015.
   

   >> Share

   
   
5. AILANI J, Lalla A, Halker Singh RB, Holle-Lee D, et al
   Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies.
   Cephalalgia. 2024;44:3331024241299377.
   

   >> Share

   
   
6. PULEDDA F, de Boer I, Messina R, Garcia-Azorin D, et al
   Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society.
   Cephalalgia. 2024;44:3331024241297688.
   

   >> Share

   
   
7. YANG C, Wei C, Alam S, Chen X, et al
   The neurotrophic factor artemin and its receptor GFRalpha3 mediate migraine-like pain via the ion channel TRPM8.
   Cephalalgia. 2024;44:3331024241297679.
   

   >> Share

   
   
8. DALLA VOLTA G, Russo A, Silvestro M, Ornello R, et al
   Exploring the multifaceted characteristics of aura in migraine: A multicenter, cross-sectional study.
   Cephalalgia. 2024;44:3331024241299453.
   

   >> Share

   
   October 2024
9. SEBASTIANELLI G, Atalar AC, Cetta I, Farham F, et al
   Insights from triggers and prodromal symptoms on how migraine attacks start: The threshold hypothesis.
   Cephalalgia. 2024;44:3331024241287224.
   

   >> Share

   
   
10. PELES I, Sharvit S, Zlotnik Y, Gordon M, et al
    Migraine and work - beyond absenteeism: Migraine severity and occupational burnout - A cohort study.
    Cephalalgia. 2024;44:3331024241289930.
    

    >> Share

    
    
11. CAMMAROTA F, De Icco R, Vaghi G, Corrado M, et al
    High-frequency episodic migraine: Time for its recognition as a migraine subtype?
    Cephalalgia. 2024;44:3331024241291578.
    

    >> Share

    
    
12. TRILLER P, Blessing VN, Overeem LH, Fitzek MP, et al
    Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study.
    Cephalalgia. 2024;44:3331024241288875.
    

    >> Share

    
    September 2024
13. ACARSOY C, Ikram MK, Ikram MA, Vernooij MW, et al
    Migraine and brain structure in the elderly: The Rotterdam Study.
    Cephalalgia. 2024;44:3331024241266951.
    

    >> Share

    
    
14. KOPRUSZINSKI CM, Lee G, Martin LK, Barber KR, et al
    A male-specific mechanism of meningeal nociceptor sensitization promoting migraine headache.
    Cephalalgia. 2024;44:3331024241281493.
    

    >> Share

    
    
15. PULEDDA F, Sacco S, Diener HC, Ashina M, et al
    International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine.
    Cephalalgia. 2024;44:3331024241269735.
    

    >> Share

    
    
16. IHARA K, Casillo F, Dahshan A, Genc H, et al
    Are we closer to achieving precision medicine for migraine treatment? A narrative review.
    Cephalalgia. 2024;44:3331024241281518.
    

    >> Share

    
    
17. MELO-CARRILLO A, Strassman AM, Malcolm KJ, Adams AM, et al
    Exploring the effects of extracranial injections of botulinum toxin type A on activation and sensitization of central trigeminovascular neurons by cortical spreading depression in male and female rats.
    Cephalalgia. 2024;44:3331024241278919.
    

    >> Share

    
    
18. WILCHA RJ, Goadsby PJ
    Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study.
    Cephalalgia. 2024;44:3331024241278911.
    

    >> Share

    
    
19. CASILLO F, Di Renzo A, Sebastianelli G, Abagnale C, et al
    Lack of a direct link between macular cones function and photophobia in interictal migraine.
    Cephalalgia. 2024;44:3331024241276501.
    

    >> Share

    
    
20. ASHINA M, Steiner TJ, Hansen JM, Hauberg DS, et al
    Cost of illness and labour market disaffiliation among patients with migraine discontinuing triptan treatment: A Danish nationwide register study from 1995 to 2021.
    Cephalalgia. 2024;44:3331024241269758.
    

    >> Share

    
    
21. ERNSTSEN C, Obelitz-Ryom K, Kristensen DMB, Olesen J, et al
    Mechanisms of GTN-induced migraine: Role of NOS isoforms, sGC and peroxynitrite in a migraine relevant mouse model.
    Cephalalgia. 2024;44:3331024241277542.
    

    >> Share

    
    
22. ELOSUA-BAYES I, Alpuente A, Melgarejo L, Caronna E, et al
    Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data.
    Cephalalgia. 2024;44:3331024241273966.
    

    >> Share

    
    August 2024
23. DO TP
    Clarification on the incidence and sex-specificity of sexual dysfunction as an adverse event of CGRP-targeting medications.
    Cephalalgia. 2024;44:3331024241268058.
    

    >> Share

    
    
24. OMLAND PM
    Enhanced learning in migraine: False positive finding or discovery of a new migraine trait?
    Cephalalgia. 2024;44:3331024241268297.
    

    >> Share

    
    
25. STUBBERUD A, Borkenhagen S, Oteiza F, Dueland AN, et al
    Patterns of migraine medication use in Norway: A nationwide registry-based observational study.
    Cephalalgia. 2024;44:3331024241268212.
    

    >> Share

    
    
26. PULEDDA F, Sacco S, Diener HC, Ashina M, et al
    International Headache Society global practice recommendations for the acute pharmacological treatment of migraine.
    Cephalalgia. 2024;44:3331024241252666.
    

    >> Share

    
    
27. KATSARAVA Z, Buse DC, Leroux E, Lanteri-Minet M, et al
    Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study.
    Cephalalgia. 2024;44:3331024241274343.
    

    >> Share

    
    
28. SIMMONDS L, Jamtoy KA, Aschehoug I, Hara S, et al
    Open label experience of repeated OnabotulinumtoxinA injections towards the sphenopalatine ganglion in patients with chronic cluster headache and chronic migraine.
    Cephalalgia. 2024;44:3331024241273967.
    

    >> Share

    
    
29. THOMSEN AV, Al-Karagholi MA, Hougaard A, Ostrowski SR, et al
    Effects of levcromakalim in patients with migraine aura without headache: An experimental study.
    Cephalalgia. 2024;44:3331024241274366.
    

    >> Share

    
    
30. HU YY, Souza R, Muthuraman A, Knapp L, et al
    Glucocorticoid signaling mediates stress-induced migraine-like behaviors in a preclinical mouse model.
    Cephalalgia. 2024;44:3331024241277941.
    

    >> Share

    
    
31. MULLIN K, Croop R, Mosher L, Fullerton T, et al
    Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study.
    Cephalalgia. 2024;44:3331024241259456.
    

    >> Share

    
    
32. AL-KHAZALI HM, Al-Sayegh Z, Younis S, Christensen RH, et al
    Systematic review and meta-analysis of Neck Disability Index and Numeric Pain Rating Scale in patients with migraine and tension-type headache.
    Cephalalgia. 2024;44:3331024241274266.
    

    >> Share

    
    
33. PERES MFP, Sacco S, Pozo-Rosich P, Tassorelli C, et al
    Migraine is the most disabling neurological disease among children and adolescents, and second after stroke among adults: A call to action.
    Cephalalgia. 2024;44:3331024241267309.
    

    >> Share

    
    July 2024
34. RUSCHEWEYH R, Forderreuther S, Freilinger T, Gaul C, et al
    Minimal important difference of the Migraine Disability Assessment (MIDAS): Longitudinal data from the DMKG Headache Registry.
    Cephalalgia. 2024 Jul 21:3331024241261077. doi: 10.1177/03331024241261077.
    

    >> Share

    
    
35. DE VRIES T, Boucherie DM, Chan KY, Rubio-Beltran E, et al
    Sex differences in CGRP-induced vasodilation of human middle meningeal arteries but not human coronary arteries: implications for migraine.
    Cephalalgia. 2024;44:3331024241254088.
    

    >> Share

    
    
36. TOT K, Braunitzer G, Harcsa-Pinter N, Kiss A, et al
    Enhanced audiovisual associative pair learning in migraine without aura in adult patients: An unexpected finding.
    Cephalalgia. 2024;44:3331024241258722.
    

    >> Share

    
    June 2024
37. EXACOUSTOS C, Martire FG, Albanese M, Selntigia A, et al
    REPLY to Comment on Correlation between endometriosis and migraine features: Results from a prospective case-control study'': Correlation between endometriosis and migraine features is not based on a broad strokes results.
    Cephalalgia. 2024;44:3331024241254821.
    

    >> Share

    
    
38. LIU L, Chen Q, Zhao L, Lyu T, et al
    Acupuncture plus topiramate placebo versus topiramate plus sham acupuncture for the preventive treatment of chronic migraine: A single-blind, double-dummy, randomized controlled trial.
    Cephalalgia. 2024;44:3331024241261080.
    

    >> Share

    
    
39. ISHII R, Ishizuchi K, Watanabe N, Fukazawa R, et al
    Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan.
    Cephalalgia. 2024;44:3331024241258695.
    

    >> Share

    
    
40. AL-KHAZALI HM, Ashina H, Christensen RH, Wiggers A, et al
    Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab.
    Cephalalgia. 2024;44:3331024241258734.
    

    >> Share

    
    
41. RAFFAELLI B, Do TP, Ashina H, Snellman J, et al
    Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation.
    Cephalalgia. 2024;44:3331024241259489.
    

    >> Share

    
    
42. LI H, Xu X, Xu R, Fan PX, et al
    Latent class analysis of migraine associated vestibular-auditory symptoms.
    Cephalalgia. 2024;44:3331024241262488.
    

    >> Share

    
    
43. BRAILLON A
    Registry-based safety studies of migraine drugs in pregnancy: Acknowledging our failures.
    Cephalalgia. 2024;44:3331024241262486.
    

    >> Share

    
    
44. 
    Corrigendum to "Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials".
    Cephalalgia. 2024;44:3331024241255216.
    

    >> Share

    
    
45. 
    Corrigendum to: Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Cephalalgia. 2024;44:3331024241254952.
    

    >> Share

    
    May 2024
46. RASMUSSEN AV, Jensen RH, Gantenbein A, Sumelahti ML, et al
    Consensus recommendations on the role of nurses in headache care: A European e-Delphi study.
    Cephalalgia. 2024;44:3331024241252161.
    

    >> Share

    
    
47. KOKOTI L, Al-Karagholi MA, Zhuang ZA, Amirguliyev S, et al
    Non-vascular ATP-sensitive potassium channel activation does not trigger migraine attacks: A randomized clinical trial.
    Cephalalgia. 2024;44:3331024241248211.
    

    >> Share

    
    
48. AKGOR U, Ince O
    Comment on ''Correlation between endometriosis and migraine features: Results from a prospective case-control study''.
    Cephalalgia. 2024;44:3331024241254824.
    

    >> Share

    
    
49. GIRI S, Tronvik E, Dalen H, Ellekjaer H, et al
    Migraine and risk of atrial fibrillation: A 9-year follow-up based on the Trondelag Health Study.
    Cephalalgia. 2024;44:3331024241254517.
    

    >> Share

    
    
50. AL-HASSANY L, Boucherie DM, Couturier EGM, MaassenVanDenBrink A, et al
    Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?
    Cephalalgia. 2024;44:3331024241248837.
    

    >> Share

    
    April 2024
51. RATTANAWONG W, Rapoport A, Srikiatkhachorn A
    Medication "underuse" headache.
    Cephalalgia. 2024;44:3331024241245658.
    

    >> Share

    
    
52. MITTER VR, Lupattelli A, Bjork MH, Nordeng HME, et al
    Identification and characterization of migraine in pregnancy: A Norwegian registry-based cohort study.
    Cephalalgia. 2024;44:3331024241248846.
    

    >> Share

    
    
53. GARCIA-AZORIN D, Martinez-Badillo C, Camina Muniz J, Gago-Veiga AB, et al
    CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine.
    Cephalalgia. 2024;44:3331024241248833.
    

    >> Share

    
    
54. WHITAKER DJ, Dumkrieger GM, Hentz JG, Dodick DW, et al
    Physical impairment during and between migraine attacks: A daily diary study of patients with chronic migraine.
    Cephalalgia. 2024;44:3331024241249747.
    

    >> Share

    
    
55. CROOP R, Berman G, Kudrow D, Mullin K, et al
    A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.
    Cephalalgia. 2024;44:3331024241232944.
    

    >> Share

    
    
56. OLFAT M, Hosseinpour S, Masoumi S, Gogia Rastogi R, et al
    A comparative study on prophylactic efficacy of cinnarizine and amitriptyline in childhood migraine: a randomized double-blind clinical trial.
    Cephalalgia. 2024;44:3331024241230963.
    

    >> Share

    
    March 2024
57. PASCUAL-MATO M, Garate G, de Prado-Tejerina C, Garcia MJ, et al
    Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study.
    Cephalalgia. 2024;44:3331024241233979.
    

    >> Share

    
    
58. SELNTIGIA A, Exacoustos C, Ortoleva C, Russo C, et al
    Correlation between endometriosis and migraine features: Results from a prospective case-control study.
    Cephalalgia. 2024;44:3331024241235210.
    

    >> Share

    
    
59. PORRECA F, Navratilova E, Hirman J, van den Brink AM, et al
    Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Cephalalgia. 2024;44:3331024241238153.
    

    >> Share

    
    
60. THOMSEN AV, Al-Karagholi MA, Hougaard A, Ostrowski SR, et al
    Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura.
    Cephalalgia. 2024;44:3331024241237247.
    

    >> Share

    
    
61. LAMAS PEREZ R, Millan-Vazquez M, Gonzalez-Oria C
    Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: Observational prospective study.
    Cephalalgia. 2024;44:3331024231226181.
    

    >> Share

    
    
62. SACCO S, Porreca F
    Breaking barriers in migraine care: Advancing gender medicine to bridge the gap for men.
    Cephalalgia. 2024;44:3331024241238157.
    

    >> Share

    
    
63. DIENER HC, May A
    New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication.
    Cephalalgia. 2024;44:3331024241228605.
    

    >> Share

    
    
64. ASHINA H, Diener HC, Tassorelli C, Scher AI, et al
    Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury.
    Cephalalgia. 2024;44:3331024241234068.
    

    >> Share

    
    February 2024
65. TORRES-FERRUS M, Gallardo VJ, Alpuente A, Caronna E, et al
    Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies.
    Cephalalgia. 2024;44:3331024231222923.
    

    >> Share

    
    
66. THURAIAIYAH J, Ashina H, Christensen RH, Al-Khazali HM, et al
    Premonitory symptoms in migraine: A REFORM Study.
    Cephalalgia. 2024;44:3331024231223979.
    

    >> Share

    
    
67. PHILLIPS K, Clerkin-Oliver C, Nirantharakumar K, Crowe FL, et al
    How migraine and its associated treatment impact on pregnancy outcomes: Umbrella review with updated systematic review and meta-analysis.
    Cephalalgia. 2024;44:3331024241229410.
    

    >> Share

    
    
68. VIANA M, Hougaard A, Tronvik E, Winnberg IG, et al
    Visual migraine aura iconography: A multicentre, cross-sectional study of individuals with migraine with aura.
    Cephalalgia. 2024;44:3331024241234809.
    

    >> Share

    
    
69. IKUMI N, Marti-Marca A, Torre-Sune A, Cerda-Company X, et al
    Quantifying sensory thresholds along the migraine cycle: An exploratory longitudinal study.
    Cephalalgia. 2024;44:3331024241230279.
    

    >> Share

    
    
70. TASSORELLI C, Onishchenko K, Halker Singh RB, Duan M, et al
    Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
    Cephalalgia. 2024;44:3331024241235156.
    

    >> Share

    
    
71. SHEWALE AR, Brandenburg JA, Burslem K, Lipton RB, et al
    Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine.
    Cephalalgia. 2024;44:3331024241235139.
    

    >> Share

    
    January 2024
72. COPPOLA G, Renzo AD, Parisi V, Serrao M, et al
    Comment on "Lack of reproducibility of resting-state functional MRI findings in migraine with aura".
    Cephalalgia. 2024;44:3331024231225186.
    

    >> Share

    
    
73. PICO MJ, Badri M, Michalak N, Siefferman JW, et al
    Systemic allergic reaction to galcanezumab (emgality): a case report.
    Cephalalgia. 2024;44:3331024231222914.
    

    >> Share

    
    
74. NIDDAM DM, Lai KL, Hsiao YT, Wang YF, et al
    Grey matter structure within the visual networks in migraine with aura: multivariate and univariate analyses.
    Cephalalgia. 2024;44:3331024231222637.
    

    >> Share

    
    
75. BUGGE NS, Grotta Vetvik K, Alstadhaug KB, Braaten T, et al
    Cumulative exposure to estrogen may increase the risk of migraine in women.
    Cephalalgia. 2024;44:3331024231225972.
    

    >> Share

    
    
76. FLORESCU AM, Lannov LV, Younis S, Cullum CK, et al
    No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study.
    Cephalalgia. 2024;44:3331024231222915.
    

    >> Share

    
    
77. RAHMAN SM, Luebke AE
    Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models.
    Cephalalgia. 2024;44:3331024231223971.
    

    >> Share

    
    
78. RAFFAELLI B, Do TP, Chaudhry BA, Amin FM, et al
    Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors: a randomized placebo-controlled trial.
    Cephalalgia. 2024;44:3331024231222916.
    

    >> Share

    
    
79. MONTE G, Papetti L, Ursitti F, Sforza G, et al
    Childhood primary stabbing headache: A double center study.
    Cephalalgia. 2024;44:3331024231225974.
    

    >> Share

    
    
80. KRISTOFFERSEN ES, Pallesen S, Waage S, Bjorvatn B, et al
    The long-term effect of work schedule, shift work disorder, insomnia and restless legs syndrome on headache among nurses: A prospective longitudinal cohort study.
    Cephalalgia. 2024;44:3331024231226323.
    

    >> Share

    
    December 2023
81. BASEDAU H, Ornello R, Matteis E, Davaasuren B, et al
    Placebo and nocebo in the treatment of migraine: How much does real world effectiveness depend on contextual effects?
    Cephalalgia. 2023;43:3331024231218392.
    

    >> Share

    
    
82. PENSATO U, Cevoli S, Pierangeli G, Cortelli P, et al
    The evolutionary meaning of migraine.
    Cephalalgia. 2023;43:3331024231209303.
    

    >> Share

    
    
83. TEZUKA T, Shibata M, Hanaoka H, Izawa Y, et al
    Systemic lupus erythematosus mimicking retinal migraine: a case report.
    Cephalalgia. 2023;43:3331024231219477.
    

    >> Share

    
    
84. DOBOS D, Kokonyei G, Gyebnar G, Szabo E, et al
    Microstructural differences in migraine: A diffusion-tensor imaging study.
    Cephalalgia. 2023;43:3331024231216456.
    

    >> Share

    
    
85. AL-KARAGHOLI MA
    Targeting CGRP pathways and aura: A peripheral site with a central effect.
    Cephalalgia. 2023;43:3331024231212895.
    

    >> Share

    
    
86. CHRISTOPHERSEN P, Dyhring T
    The shortcoming of using glibenclamide in exploratory clinical headache provocation studies.
    Cephalalgia. 2023;43:3331024231219475.
    

    >> Share

    
    November 2023
87. VAN DER AREND B, Terwindt GM
    Response to Letter to the Editor, Comment on "Effect of COVID vaccinations on monthly migraine days".
    Cephalalgia. 2023;43:3331024231208123.
    

    >> Share

    
    
88. DAUNGSUPAWONG H, Wiwanitkit V
    Comment on "Effect of COVID vaccination on monthly migraine days".
    Cephalalgia. 2023;43:3331024231208121.
    

    >> Share

    
    
89. AL-KHAZALI HM, Christensen RH, Dodick DW, Chaudhry BA, et al
    Hypersensitivity to opening of ATP-sensitive potassium channels in post-traumatic headache.
    Cephalalgia. 2023;43:3331024231210930.
    

    >> Share

    
    
90. NAVARRO-PEREZ MP, Santos-Lasaosa S, Olesen J
    Evaluation of the ICHD-3 diagnostic criteria for cardiac cephalalgia and new proposal.
    Cephalalgia. 2023;43:3331024231202243.
    

    >> Share

    
    
91. HOUGAARD A, Gaist D, Garde E, Iversen P, et al
    Lack of reproducibility of resting-state functional MRI findings in migraine with aura.
    Cephalalgia. 2023;43:3331024231212574.
    

    >> Share

    
    
92. BAHRA A
    Paroxysmal hemicrania and hemicrania continua: Review on pathophysiology, clinical features and treatment.
    Cephalalgia. 2023;43:3331024231214239.
    

    >> Share

    
    
93. GARCIA-AZORIN D, Santana-Lopez L, Lozano-Alonso JE, Ordax-Diez A, et al
    InfluenCEF study: Clinical phenotype and duration of headache attributed to influenza infection.
    Cephalalgia. 2023;43:3331024231212900.
    

    >> Share

    
    
94. ASHINA M, Mitsikostas DD, Amin FM, Kokturk P, et al
    Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
    Cephalalgia. 2023;43:3331024231214987.
    

    >> Share

    
    October 2023
95. SEBASTIANELLI G, Casillo F, Abagnale C, Renzo AD, et al
    Central sensitization mechanisms in chronic migraine with medication overuse headache: a study of thalamocortical activation and lateral cortical inhibition.
    Cephalalgia. 2023;43:3331024231202240.
    

    >> Share

    
    
96. AL-KHAZALI HM, Ashina H, Christensen RH, Wiggers A, et al
    An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study.
    Cephalalgia. 2023;43:3331024231206375.
    

    >> Share

    
    
97. DEV P, Favas TT, Jaiswal R, Cyriac M, et al
    The effect of low dose thyroid replacement therapy in patients with episodic migraine and subclinical hypothyroidism: A randomised placebo-controlled trial.
    Cephalalgia. 2023;43:3331024231182684.
    

    >> Share

    
    
98. CHUANG CH, Li JY, King JT, Chen WT, et al
    Abnormal heart rate variability and its application in predicting treatment efficacy in patients with chronic migraine: An exploratory study.
    Cephalalgia. 2023;43:3331024231206781.
    

    >> Share

    
    
99. CHRISTENSEN RH, Eigenbrodt AK, Ashina H, Steiner TJ, et al
    What proportion of people with migraine report postdromal symptoms? A systematic review and meta-analysis of observational studies.
    Cephalalgia. 2023;43:3331024231206376.
    

    >> Share

    
    
100. KUAN AS, Chen SP, Wang YF, Wang SJ, et al
     Prolonged headache with vaccine- and dose-specific headache pattern associated with vaccine against SARS-CoV-2 in patients with migraine.
     Cephalalgia. 2023;43:3331024231208110.
     

     >> Share

     
     
101. ZLOOF Y, Tsur AM, Simchoni M, Derazne E, et al
     Body mass index and migraine in adolescence: A nationwide study.
     Cephalalgia. 2023;43:3331024231209309.
     

     >> Share

     
     
102. ALEKSOVSKA K, Hershey AD, Deen M, Icco R, et al
     Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society.
     Cephalalgia. 2023;43:3331024231206162.
     

     >> Share

     
     
103. BELIN AC, Barloese MC
     The genetics and chronobiology of cluster headache.
     Cephalalgia. 2023;43:3331024231208126.
     

     >> Share

     
     September 2023
104. VAN DER AREND BWH, Bloemhof MM, van der Schoor AG, van Zwet EW, et al
     Effect of COVID vaccination on monthly migraine days: a longitudinal cohort study.
     Cephalalgia. 2023;43:3331024231198792.
     

     >> Share

     
     August 2023
105. ALPUENTE A, Torre-Sune A, Caronna E, Gine-Cipres E, et al
     Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study.
     Cephalalgia. 2023;43:3331024231177636.
     

     >> Share

     
     
106. LA ROCCA M, Laporta A, Clemente L, Ammendola E, et al
     Galcanezumab treatment changes visual related EEG connectivity patterns in migraine patients.
     Cephalalgia. 2023;43:3331024231189751.
     

     >> Share

     
     
107. ADAM I, Elmugabil A, AlHabardi N
     History of maternal migraine and its association with preeclampsia: A case-control study in a low-resource setting in Sudan, Africa.
     Cephalalgia. 2023;43:3000605231193823.
     

     >> Share

     
     
108. PULEDDA F, Vigano A, Sebastianelli G, Parisi V, et al
     Electrophysiological findings in migraine may reflect abnormal synaptic plasticity mechanisms: A narrative review.
     Cephalalgia. 2023;43:3331024231195780.
     

     >> Share

     
     
109. LIPTON RB, Halker Singh RB, Mechtler L, McVige J, et al
     Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
     Cephalalgia. 2023;51:3331024231190296.
     

     >> Share

     
     July 2023
110. PATTERSON GENTILE C, Aguirre GK, Hershey AD, Szperka CL, et al
     Symptoms associated with headache in youth.
     Cephalalgia. 2023;43:3331024231187162.
     

     >> Share

     
     June 2023
111. VERHAGEN IE, van der Arend BW, van Casteren DS, Thiermann NJ, et al
     Migraine with and without aura in relation to the menstrual cycle and other hormonal milestones: A prospective cohort study.
     Cephalalgia. 2023;43:3331024231164322.
     

     >> Share

     
     
112. PELZER N, de Boer I, van den Maagdenberg AMJM, Terwindt GM, et al
     Neurological and psychiatric comorbidities of migraine: Concepts and future perspectives.
     Cephalalgia. 2023;43:3331024231180564.
     

     >> Share

     
     
113. KLAN T, Gaul C, Liesering-Latta E, Witthoft M, et al
     Behavioral treatment for migraine prophylaxis in adults: Moderator analysis of a randomized controlled trial.
     Cephalalgia. 2023;43:3331024231178237.
     

     >> Share

     
     
114. BERTZ R, Bhardwaj R, Morris BA, Ashbrenner E, et al
     A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants.
     Cephalalgia. 2023;43:3331024231179131.
     

     >> Share

     
     
115. BUTURE A, Tomkins EM, Shukralla A, Troy E, et al
     Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the
     Cephalalgia. 2023;43:3331024231182126.
     

     >> Share

     
     
116. ADAMS AM, Buse DC, Leroux E, Lanteri-Minet M, et al
     Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care.
     Cephalalgia. 2023;43:3331024231180611.
     

     >> Share

     
     
117. CARCEL C, Haghdoost F, Shen J, Nanda P, et al
     The effect of blood pressure lowering medications on the prevention of episodic migraine: A systematic review and meta-analysis.
     Cephalalgia. 2023;43:3331024231183166.
     

     >> Share

     
     
118. THOMSEN AV, Puonti O, Gaist D, Kyvik KO, et al
     Investigations of the subarachnoid space as a potential link between aura and headache in migraine: A case-control MRI study.
     Cephalalgia. 2023;43:3331024231170541.
     

     >> Share

     
     
119. CONSTANTINIDIS TS, Arvaniti C, Fakas N, Rudolf J, et al
     The prevalence and burden of medication overuse headache in Greece.
     Cephalalgia. 2023;43:3331024231184909.
     

     >> Share

     
     May 2023
120. VAN DER AREND BWH, Verhagen IE, van Leeuwen M, van der Arend MQTP, et al
     Defining migraine days, based on longitudinal E-diary data.
     Cephalalgia. 2023;43:3331024231166625.
     

     >> Share

     
     
121. CHEEMA S, Mehta D, Ray JC, Hutton EJ, et al
     New daily persistent headache: A systematic review and meta-analysis.
     Cephalalgia. 2023;43:3331024231168089.
     

     >> Share

     
     
122. STUBBERUD A, Ingvaldsen SH, Brenner E, Winnberg I, et al
     Forecasting migraine with machine learning based on mobile phone diary and wearable data.
     Cephalalgia. 2023;43:3331024231169244.
     

     >> Share

     
     
123. ASHINA M, Lanteri-Minet M, Ettrup A, Christoffersen CL, et al
     Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
     Cephalalgia. 2023;43:3331024231170807.
     

     >> Share

     
     
124. VAN WELIE RF, van Welie FC, de Vries Lentsch S, Dahan A, et al
     Characterizing opioid use in a Dutch cohort with migraine.
     Cephalalgia. 2023;43:3331024231174160.
     

     >> Share

     
     
125. HSIAO FJ, Chen WT, Wang YF, Chen SP, et al
     Identification of patients with chronic migraine by using sensory-evoked oscillations from the electroencephalogram classifier.
     Cephalalgia. 2023;43:3331024231176074.
     

     >> Share

     
     
126. GULDIKEN YC, Petropoulos IN, Malik A, Malik RA, et al
     Corneal confocal microscopy identifies corneal nerve fiber loss in patients with migraine.
     Cephalalgia. 2023;43:3331024231170810.
     

     >> Share

     
     
127. RUSCHEWEYH R, Dresler T, Forderreuther S, Gaul C, et al
     What do patients' efficacy and tolerability ratings of acute migraine medication tell us? Cross-sectional data from the DMKG Headache Registry.
     Cephalalgia. 2023;43:3331024231174855.
     

     >> Share

     
     
128. STEINER TJ
     Classification of migraine and tension-type headache: A response to the proposals of Olesen.
     Cephalalgia. 2023;43:3331024231169240.
     

     >> Share

     
     
129. SUZUKI K, Suzuki S, Shiina T, Tatsumoto M, et al
     Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
     Cephalalgia. 2023;43:3331024231177649.
     

     >> Share

     
     
130. PARK CG, Na HY, Park DE, Kim HY, et al
     Altered interictal serum histamine and immunoglobulin E but unchanged tryptase levels in individuals with episodic and chronic migraine.
     Cephalalgia. 2023;43:3331024231178218.
     

     >> Share

     
     
131. ABU-ARAFEH I, Hershey AD, Diener HC, Tassorelli C, et al
     Guidelines Update: Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition - An experience-based update.
     Cephalalgia. 2023;43:3331024231178239.
     

     >> Share

     
     April 2023
132. GIRI S, Tronvik E, Linde M, Pedersen SA, et al
     Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
     Cephalalgia. 2023;43:3331024231156922.
     

     >> Share

     
     
133. OLESEN J, Jensen RH
     The Global Campaign Against Headache and its future relation to IHS and WHO.
     Cephalalgia. 2023;43:3331024231159625.
     

     >> Share

     
     
134. HAGHDOOST F, Puledda F, Garcia-Azorin D, Huessler EM, et al
     Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
     Cephalalgia. 2023;43:3331024231159366.
     

     >> Share

     
     
135. NIDDAM DM, Wu SW, Lai KL, Yang YY, et al
     An altered reward system characterizes chronic migraine with medication overuse headache.
     Cephalalgia. 2023;43:3331024231158088.
     

     >> Share

     
     
136. ASAWAVICHIENJINDA T, Sathitratanacheewin S, Chokesuwattanaskul R
     "Wearing-off" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials.
     Cephalalgia. 2023;43:3331024231161261.
     

     >> Share

     
     
137. IANNONE LF, Burgalassi A, Vigani G, Tabasso G, et al
     Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
     Cephalalgia. 2023;43:3331024231160519.
     

     >> Share

     
     
138. FAVONI V, Mascarella D, Giannini G, Bauleo S, et al
     Prevalence, natural history and dynamic nature of chronic headache and medication overuse headache in Italy: The SPARTACUS study.
     Cephalalgia. 2023;43:3331024231157677.
     

     >> Share

     
     
139. ASHINA M, Roos C, Li LQ, Komori M, et al
     Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial.
     Cephalalgia. 2023;43:3331024231161745.
     

     >> Share

     
     
140. ZHANG L, Zhou Y, Wang Y, Yang L, et al
     Inhibiting PAC1 receptor internalization and endosomal ERK pathway activation may ameliorate hyperalgesia in a chronic migraine rat model.
     Cephalalgia. 2023;43:3331024231163131.
     

     >> Share

     
     
141. RUSSO CV, Sacca F, Braca S, Sansone M, et al
     Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study.
     Cephalalgia. 2023;43:3331024231161809.
     

     >> Share

     
     
142. OLESEN J
     Classification of migraine and tension-type headache.
     Cephalalgia. 2023;43:3331024221139238.
     

     >> Share

     
     
143. CROWE HM, Wesselink AK, Hatch EE, Wise LA, et al
     Migraine and risk of hypertensive disorders of pregnancy: A population-based cohort study.
     Cephalalgia. 2023;43:3331024231161746.
     

     >> Share

     
     
144. SAKAI F, Igarashi H, Yokoyama M, Begasse de Dhaem O, et al
     Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employees.
     Cephalalgia. 2023;43:3331024231165682.
     

     >> Share

     
     March 2023
145. MESSINA R, Huessler EM, Puledda F, Haghdoost F, et al
     Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
     Cephalalgia. 2023;43:3331024231152169.
     

     >> Share

     
     
146. MYKLAND MS, Uglem M, Bjork MH, Matre D, et al
     Effects of insufficient sleep on sensorimotor processing in migraine: A randomised, blinded crossover study of event related beta oscillations.
     Cephalalgia. 2023;43:3331024221148398.
     

     >> Share

     
     
147. PULEDDA F, Tassorelli C, Diener HC
     New migraine drugs.
     Cephalalgia. 2023;43:3331024221144784.
     

     >> Share

     
     
148. LEE MJ, Peng KP
     Other primary headaches: Distinct clinical features and uncertain pathophysiology.
     Cephalalgia. 2023;43:3331024221147870.
     

     >> Share

     
     
149. PULEDDA F, Younis S, Huessler EM, Haghdoost F, et al
     Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature.
     Cephalalgia. 2023;43:3331024231151419.
     

     >> Share

     
     
150. CARLSEN LN, Hansen CS, Kogelman LJA, Werge TM, et al
     DNA-methylation and immunological response in medication overuse headache.
     Cephalalgia. 2023;43:3331024221147482.
     

     >> Share

     
     
151. EVERS S
     Cephalalgia - The early history.
     Cephalalgia. 2023;43:3331024221148128.
     

     >> Share

     
     
152. MYKLAND MS, Uglem M, Stovner LJ, Brenner E, et al
     Insufficient sleep may alter cortical excitability near the migraine attack: A blinded TMS crossover study.
     Cephalalgia. 2023;43:3331024221148391.
     

     >> Share

     
     
153. ASHINA S, Melo-Carrillo A, Szabo E, Borsook D, et al
     Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: A prospective quantitative sensory testing study (NCT04271202).
     Cephalalgia. 2023;43:3331024221147881.
     

     >> Share

     
     February 2023
154. RAFFAELLI B, De Icco R, Corrado M, Terhart M, et al
     Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review.
     Cephalalgia. 2023;43:3331024221137091.
     

     >> Share

     
     
155. AL-KARAGHOLI MA, Kalatharan V, Ghanizada H, Gram C, et al
     Prolactin in headache and migraine: A systematic review of clinical studies.
     Cephalalgia. 2023;43:3331024221136286.
     

     >> Share

     
     
156. LEE MJ, Al-Karagholi MA, Reuter U
     New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy.
     Cephalalgia. 2023;43:3331024221146315.
     

     >> Share

     
     
157. HARDER AV, Terwindt GM, Nyholt DR, van den Maagdenberg AM, et al
     Migraine genetics: Status and road forward.
     Cephalalgia. 2023;43:3331024221145962.
     

     >> Share

     
     
158. GALLARDO VJ, Vila-Pueyo M, Pozo-Rosich P
     The impact of epigenetic mechanisms in migraine: Current knowledge and future directions.
     Cephalalgia. 2023;43:3331024221145916.
     

     >> Share

     
     
159. NIKOLOVA S, Chong CD, Dumkrieger GM, Li J, et al
     Longitudinal differences in iron deposition in periaqueductal gray matter and anterior cingulate cortex are associated with response to erenumab in migraine.
     Cephalalgia. 2023;43:3331024221144783.
     

     >> Share

     
     
160. KWON S, Lee MJ, Kim M
     Epicranial headache part 1: Primary stabbing headache.
     Cephalalgia. 2023;43:3331024221146985.
     

     >> Share

     
     
161. SCHRAMM S, Borner C, Reichert M, Baum T, et al
     Functional magnetic resonance imaging in migraine: A systematic review.
     Cephalalgia. 2023;43:3331024221128278.
     

     >> Share

     
     
162. DE BOER I, Verhagen IE, Souza MNP, Ashina M, et al
     Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies.
     Cephalalgia. 2023;43:3331024221143773.
     

     >> Share

     
     
163. RUIZ M, Cocores A, Tosti A, Goadsby PJ, et al
     Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review.
     Cephalalgia. 2023;43:3331024221143538.
     

     >> Share

     
     
164. CHOWDHURY D, Tomar A, Deorari V, Duggal A, et al
     Greater occipital nerve blockade for the preventive treatment of chronic migraine: A randomized double-blind placebo-controlled study.
     Cephalalgia. 2023;43:3331024221143541.
     

     >> Share

     
     
165. LIPTON RB, Blumenfeld A, Jensen CM, Croop R, et al
     Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials.
     Cephalalgia. 2023;43:3331024221141686.
     

     >> Share

     
     
166. MEISE R, Carvalho GF, Thiel C, Luedtke K, et al
     Additional effects of pain neuroscience education combined with physiotherapy on the headache frequency of adult patients with migraine: A randomized controlled trial.
     Cephalalgia. 2023;43:3331024221144781.
     

     >> Share

     
     
167. TASNIM S, Wilson SG, Walsh JP, Nyholt DR, et al
     Shared genetics and causal relationships between migraine and thyroid function traits.
     Cephalalgia. 2023;43:3331024221139253.
     

     >> Share

     
     
168. BEGASSE DE DHAEM O, Takizawa T, Dodick DW
     Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks.
     Cephalalgia. 2023;43:3331024221137092.
     

     >> Share

     
     
169. VILA-PUEYO M, Cuenca-Leon E, Queiros AC, Kulis M, et al
     Genome-wide DNA methylation analysis in an antimigraine-treated preclinical model of cortical spreading depolarization.
     Cephalalgia. 2023;43:3331024221146317.
     

     >> Share

     
     January 2023
170. PATTERSON GENTILE C, Aguirre GK, Hershey AD, Szperka CL, et al
     Comparison of continuous headache features in youth with migraine, new daily persistent headache, and persistent post-traumatic headache.
     Cephalalgia. 2023;43:3331024221131331.
     

     >> Share

     
     
171. SCUTELNIC A, Petroulia V, Schraml L, Jung S, et al
     The "index vein" as a sign for migraine aura in the emergency setting.
     Cephalalgia. 2023;43:3331024221132010.
     

     >> Share

     
     
172. ACARSOY C, Fani L, Al-Hassany L, Berghout B, et al
     Migraine and the risk of stroke in a middle-aged and elderly population: A prospective cohort study.
     Cephalalgia. 2023;43:3331024221132008.
     

     >> Share

     
     
173. KURTH T, Rohmann JL
     Studying migraine as a risk factor for stroke: The importance of working with an explicit causal framework.
     Cephalalgia. 2023;43:3331024221132007.
     

     >> Share

     
     
174. KLEIN BC, Miceli R, Severt L, McAllister P, et al
     Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
     Cephalalgia. 2023;43:3331024221128250.
     

     >> Share

     
     
175. PACHECO-BARRIOS K, Velasquez-Rimachi V, Navarro-Flores A, Huerta-Rosario A, et al
     Primary headache disorders in Latin America and the Caribbean: A meta-analysis of population-based studies.
     Cephalalgia. 2023;43:3331024221128265.
     

     >> Share

     
     
176. CARONNA E, van den Hoek TC, Bolay H, Garcia-Azorin D, et al
     Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review.
     Cephalalgia. 2023;43:3331024221131337.
     

     >> Share

     
     
177. FURIA A, Liguori R, Donadio V
     Recurrent Painful Ophthalmoplegic Neuropathy: A case report with atypical features and a review of the literature.
     Cephalalgia. 2023;43:3331024221133386.
     

     >> Share

     
     
178. CHWOLKA M, Goadsby PJ, Gantenbein AR
     Comorbidity or combination - more evidence for cluster-migraine?
     Cephalalgia. 2023;43:3331024221133383.
     

     >> Share

     
     November 2022
179. SAMPATAKAKIS SN, Lymperopoulos L, Mavridis T, Karagiorgis G, et al
     Visual snow: A systematic review and a case series.
     Cephalalgia. 2022;42:1409-1419.
     

     >> Share

     
     
180. CITAK A, Kilinc E, Torun IE, Ankarali S, et al
     The effects of certain TRP channels and voltage-gated KCNQ/Kv7 channel opener retigabine on calcitonin gene-related peptide release in the trigeminovascular system.
     Cephalalgia. 2022;42:1375-1386.
     

     >> Share

     
     
181. BASEDAU H, Oppermann T, Gundelwein Silva E, Peng KP, et al
     Galcanezumab modulates Capsaicin-induced C-fiber reactivity.
     Cephalalgia. 2022;42:1331-1338.
     

     >> Share

     
     October 2022
182. MARTINS-OLIVEIRA M, Akerman S, Holland PR, Tavares I, et al
     Pharmacological modulation of ventral tegmental area neurons elicits changes in trigeminovascular sensory processing and is accompanied by glycemic changes: Implications for migraine.
     Cephalalgia. 2022 Oct 18:3331024221110111. doi: 10.1177/03331024221110111.
     

     >> Share

     
     
183. RIESENBERG R, Gaul C, Stroud CE, Dong Y, et al
     Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache.
     Cephalalgia. 2022;42.
     

     >> Share

     
     
184. EVERS S, Holle-Lee D, Schankin CJ, Kull P, et al
     Visual snow syndrome is probably not mediated by CGRP: A case series.
     Cephalalgia. 2022;42.
     

     >> Share

     
     
185. LANGER LK, Bayley MT, Lawrence DW, Comper P, et al
     Revisiting the ICHD-3 criteria for headache attributed to mild traumatic injury to the head: Insights from the Toronto Concussion Study Analysis of Acute Headaches Following Concussion.
     Cephalalgia. 2022;42.
     

     >> Share

     
     
186. RAY JC, Pham X, Foster E, Cheema S, et al
     The prevalence of headache disorders in Postural Tachycardia Syndrome: A systematic review and meta-analysis of the literature.
     Cephalalgia. 2022;42.
     

     >> Share

     
     September 2022
187. LANTERI-MINET M, Ducros A, Francois C, Olewinska E, et al
     Effectiveness of onabotulinumtoxinA (BOTOX(R)) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data.
     Cephalalgia. 2022 Sep 8:3331024221123058. doi: 10.1177/03331024221123058.
     

     >> Share

     
     
188. TSAO YC, Wang YF, Fuh JL, Chen WT, et al
     Non-aura visual disturbance with high visual aura rating scale scores has stronger association with migraine chronification than typical aura.
     Cephalalgia. 2022 Sep 6:3331024221123074. doi: 10.1177/03331024221123074.
     

     >> Share

     
     
189. KELLIER DJ, Marquez de Prado B, Haagen D, Grabner P, et al
     Development of a text message-based headache diary in adolescents and children.
     Cephalalgia. 2022;42:1013-1021.
     

     >> Share

     
     August 2022
190. MACGREGOR EA, Komori M, Krege JH, Baygani S, et al
     Efficacy of lasmiditan for the acute treatment of perimenstrual migraine.
     Cephalalgia. 2022 Aug 18:3331024221118929. doi: 10.1177/03331024221118929.
     

     >> Share

     
     
191. THURAIAIYAH J, Erritzoe-Jervild M, Al-Khazali HM, Schytz HW, et al
     The role of cytokines in migraine: A systematic review.
     Cephalalgia. 2022 Aug 12:3331024221118924. doi: 10.1177/03331024221118924.
     

     >> Share

     
     
192. HENDRIKSE ER, Rees TA, Tasma Z, Le Foll C, et al
     Calcitonin receptor antibody validation and expression in the rodent brain.
     Cephalalgia. 2022;42:815-826.
     

     >> Share

     
     
193. STRASSMAN AM, Melo-Carrillo A, Houle TT, Adams A, et al
     Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.
     Cephalalgia. 2022;42:933-943.
     

     >> Share

     
     
194. THUNSTEDT DC, Schmutzer M, Fabritius MP, Thorsteinsdottir J, et al
     Headache characteristics and postoperative course in Chiari I malformation.
     Cephalalgia. 2022;42:879-887.
     

     >> Share

     
     July 2022
195. IKUMI N, Cerda-Company X, Marti-Marca A, Vila-Ballo A, et al
     Avoidance behaviour modulates but does not condition phonophobia in migraine.
     Cephalalgia. 2022 Jul 9:3331024221111772. doi: 10.1177/03331024221111772.
     

     >> Share

     
     
196. OLESEN J
     Personal view: Modelling pain mechanisms of migraine without aura.
     Cephalalgia. 2022 Jul 7:3331024221111529. doi: 10.1177/03331024221111529.
     

     >> Share

     
     
197. STEINER TJ, Terwindt GM, Katsarava Z, Pozo-Rosich P, et al
     Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process.
     Cephalalgia. 2022 Jul 5:3331024221110102. doi: 10.1177/03331024221110102.
     

     >> Share

     
     
198. VIGANO A, Toscano M, Petolicchio B, Bianchi A, et al
     Letter to the editor regarding "Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial".
     Cephalalgia. 2022 Jul 3:3331024221111528. doi: 10.1177/03331024221111528.
     

     >> Share

     
     
199. BRANDT RB, Cnossen VM, Doesborg PG, Coo IF, et al
     Unilateral increased visual sensitivity in cluster headache: a cross-sectional study.
     Cephalalgia. 2022;42:722-729.
     

     >> Share

     
     
200. ZHOU Y, Zhang F, Starcevic Manning M, Hu Z, et al
     Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions.
     Cephalalgia. 2022;42:749-760.
     

     >> Share

     
     
201. IANNONE LF, De Cesaris F, Ferrari A, Benemei S, et al
     Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine.
     Cephalalgia. 2022 Jul 1:3331024221111526. doi: 10.1177/03331024221111526.
     

     >> Share

     
     June 2022
202. MAKAREVICIUS G, Ryliskiene K
     Successful treatment of primary headache associated with sexual activity using erenumab: Case report.
     Cephalalgia. 2022;42:680-683.
     

     >> Share

     
     
203. OLIVEIRA R, Placido M, Pereira L, Machado S, et al
     Headaches and the use of personal protective equipment in the general population during the COVID-19 pandemic.
     Cephalalgia. 2022;42:608-617.
     

     >> Share

     
     
204. PENSATO U, Baraldi C, Favoni V, Mascarella D, et al
     Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.
     Cephalalgia. 2022;42:645-653.
     

     >> Share

     
     
205. RAIBIN K, Markus TE
     Cutaneous allodynia in pediatric and adolescent patients and their mothers: A comparative study.
     Cephalalgia. 2022;42:579-589.
     

     >> Share

     
     May 2022
206. SUDAT SE, Jacobson AS, Avins AL, Lipton RB, et al
     A population-health approach to characterizing migraine by comorbidity: Results from the Mindfulness and Migraine Cohort Study.
     Cephalalgia. 2022 May 31:3331024221104180. doi: 10.1177/03331024221104180.
     

     >> Share

     
     
207. CHRISTENSEN CG, Techlo TR, Kogelman LJ, Wegner Thorner L, et al
     Population-based prevalence of cranial autonomic symptoms in migraine and proposed diagnostic appendix criteria.
     Cephalalgia. 2022 May 29:3331024221094548. doi: 10.1177/03331024221094548.
     

     >> Share

     
     
208. EVERS S, Frese A, Summ O, Husstedt IW, et al
     Levetiracetam in the prophylactic treatment of episodic migraine: A prospective open label study.
     Cephalalgia. 2022 May 27:3331024221103815. doi: 10.1177/03331024221103815.
     

     >> Share

     
     
209. MOUAANAKI SA, Carlsen LN, Bendtsen L, Jensen RH, et al
     Treatment experiences and clinical characteristics in migraine and tension-type headache patients before the first visit to a tertiary headache center.
     Cephalalgia. 2022 May 27:3331024221104178. doi: 10.1177/03331024221104178.
     

     >> Share

     
     
210. VERHAGEN IE, Spaink HA, van der Arend BW, van Casteren DS, et al
     Validation of diagnostic ICHD-3 criteria for menstrual migraine.
     Cephalalgia. 2022 May 6:3331024221099031. doi: 10.1177/03331024221099031.
     

     >> Share

     
     
211. HELFENSTEIN C, Strupf M, Stefke A, Fraunberger B, et al
     Cyclic changes of sensory parameters in migraine patients.
     Cephalalgia. 2022 May 6:3331024221097932. doi: 10.1177/03331024221097932.
     

     >> Share

     
     
212. NOSER AE, Klages KL, Gamwell KL, Brammer CN, et al
     A systematic evaluation of primary headache management apps leveraging behavior change techniques.
     Cephalalgia. 2022;42:510-523.
     

     >> Share

     
     
213. CHIANG CC, Shahid AH, Harriott AM, Tietjen GE, et al
     Evaluation and treatment of headache associated with moyamoya disease - a narrative review.
     Cephalalgia. 2022;42:542-552.
     

     >> Share

     
     April 2022
214. GEPPETTI P, De Cesaris F, Benemei S, Cortelli P, et al
     Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study.
     Cephalalgia. 2022 Apr 26:3331024221093712. doi: 10.1177/03331024221093712.
     

     >> Share

     
     
215. MOHAMAD SAFIAI NI, Mohamad NA, Basri H, Inche Mat LN, et al
     High-frequency repetitive transcranial magnetic stimulation at dorsolateral prefrontal cortex for migraine prevention: A systematic review and meta-analysis.
     Cephalalgia. 2022 Apr 17:3331024221092423. doi: 10.1177/03331024221092423.
     

     >> Share

     
     
216. PAN LH, Wang YF, Ling YH, Lai KL, et al
     Pain sensitivities predict prophylactic treatment outcomes of flunarizine in chronic migraine patients: A prospective study.
     Cephalalgia. 2022 Apr 11:3331024221080572. doi: 10.1177/03331024221080572.
     

     >> Share

     
     
217. NIKOLOVA S, Schwedt TJ, Li J, Wu T, et al
     T2* reduction in patients with acute post-traumatic headache.
     Cephalalgia. 2022;42.
     

     >> Share

     
     March 2022
218. DI ANTONIO S, Arendt-Nielsen L, Ponzano M, Bovis F, et al
     Cervical musculoskeletal impairments in the 4 phases of the migraine cycle in episodic migraine patients.
     Cephalalgia. 2022 Mar 25:3331024221082506. doi: 10.1177/03331024221082506.
     

     >> Share

     
     
219. PETRUSIC I, Jovanovic V, Kovic V, Savic AM, et al
     P3 latency as a biomarker for the complexity of migraine with aura: Event-related potential study.
     Cephalalgia. 2022 Mar 25:3331024221090204. doi: 10.1177/03331024221090204.
     

     >> Share

     
     
220. BUTT JH, S Eddelien H, Kruuse C
     The headache and aura-inducing effects of sildenafil in patients with migraine with aura.
     Cephalalgia. 2022 Mar 25:3331024221088998. doi: 10.1177/03331024221088998.
     

     >> Share

     
     
221. MCALLISTER P, Kudrow D, Cady R, Hirman J, et al
     Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine.
     Cephalalgia. 2022 Mar 25:3331024221089567. doi: 10.1177/03331024221089567.
     

     >> Share

     
     
222. FERNANDEZ-DE-LAS-PENAS C, Navarro-Santana MJ, Curiel-Montero F, Plaza-Manzano G, et al
     Localized and widespread pressure pain hypersensitivity in patients with episodic or chronic migraine: A systematic review and meta-analysis.
     Cephalalgia. 2022 Mar 25:3331024221084217. doi: 10.1177/03331024221084217.
     

     >> Share

     
     
223. DIENER HC, McAllister P, Jurgens TP, Kessler Y, et al
     Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
     Cephalalgia. 2022 Mar 25:3331024221076485. doi: 10.1177/03331024221076485.
     

     >> Share

     
     
224. ASHINA M, McAllister P, Cady R, Hirman J, et al
     Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.
     Cephalalgia. 2022 Mar 18:3331024221077646. doi: 10.1177/03331024221077646.
     

     >> Share

     
     
225. WANG YF, Liao YC, Tzeng YS, Chen SP, et al
     Mutation screening and association analysis of NOTCH3 p.R544C in patients with migraine with or without aura.
     Cephalalgia. 2022 Mar 18:3331024221080891. doi: 10.1177/03331024221080891.
     

     >> Share

     
     
226. KWON S, Gil YE, Lee MJ
     Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients.
     Cephalalgia. 2022 Mar 18:3331024221076481. doi: 10.1177/03331024221076481.
     

     >> Share

     
     
227. MILOSEVIC N, Trajkovic JZ, Mijajlovic M, Milosevic J, et al
     The burden and health care use of patients with migraine and tension-type headache in post-conflict area of Serbia.
     Cephalalgia. 2022 Mar 18:3331024221082061. doi: 10.1177/03331024221082061.
     

     >> Share

     
     
228. HIRTZ C, Adam G, Raposo N, Fabre N, et al
     Diagnostic utility of T2*-weighted GRE in migraine with aura attack. The cortical veins sign.
     Cephalalgia. 2022 Mar 18:3331024221076484. doi: 10.1177/03331024221076484.
     

     >> Share

     
     
229. THURAIAIYAH J, Kokoti L, Al-Karagholi MA, Ashina M, et al
     Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies.
     Cephalalgia. 2022 Mar 18:3331024221077665. doi: 10.1177/03331024221077665.
     

     >> Share

     
     
230. CHOWDHURY D, Mundra A, Datta D, Duggal A, et al
     Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial.
     Cephalalgia. 2022 Mar 8:3331024221082077. doi: 10.1177/03331024221082077.
     

     >> Share

     
     
231. VAZ JM, Alves BM, Duarte DB, Marques LA, et al
     Quality appraisal of existing guidelines for the management of headache disorders by the AGREE II's method.
     Cephalalgia. 2022;42:239-249.
     

     >> Share

     
     February 2022
232. MATAMALA-GOMEZ M, Bottiroli S, Sances G, Allena M, et al
     Facial expressions modulate pain perception in patients with chronic migraine.
     Cephalalgia. 2022 Feb 15:3331024221075081. doi: 10.1177/03331024221075081.
     

     >> Share

     
     
233. SEBASTIANELLI G, Abagnale C, Casillo F, Cioffi E, et al
     Bimodal sensory integration in migraine: A study of the effect of visual stimulation on somatosensory evoked cortical responses.
     Cephalalgia. 2022 Feb 15:3331024221075073. doi: 10.1177/03331024221075073.
     

     >> Share

     
     
234. KIM J, Park CG, Chu MK
     Interictal plasma endothelin-1 levels do not change in individuals with episodic and chronic migraine.
     Cephalalgia. 2022 Feb 15:3331024221075616. doi: 10.1177/03331024221075616.
     

     >> Share

     
     
235. STOVNER LJ, Hagen K, Tronvik E, Bruvik Gravdahl G, et al
     FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for chronic migraine.
     Cephalalgia. 2022 Feb 15:3331024211067775. doi: 10.1177/03331024211067775.
     

     >> Share

     
     
236. NUOTTAMO ME, Happola P, Artto V, Hautakangas H, et al
     NCOR2 is a novel candidate gene for migraine-epilepsy phenotype.
     Cephalalgia. 2022 Feb 15:3331024211068065. doi: 10.1177/03331024211068065.
     

     >> Share

     
     
237. AL-KHAZALI HM, Younis S, Al-Sayegh Z, Ashina S, et al
     Prevalence of neck pain in migraine: A systematic review and meta-analysis.
     Cephalalgia. 2022 Feb 15:3331024211068073. doi: 10.1177/03331024211068073.
     

     >> Share

     
     
238. MESSLINGER K, Neuhuber W, May A
     Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19.
     Cephalalgia. 2022;42:176-180.
     

     >> Share

     
     January 2022
239. NAJIB U, Smith T, Hindiyeh N, Saper J, et al
     Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial.
     Cephalalgia. 2022 Jan 9:3331024211068813. doi: 10.1177/03331024211068813.
     

     >> Share

     
     
240. MCGINLEY JS, Houts CR, Wirth RJ, Lipton RB, et al
     Measuring headache day severity using multiple features in daily diary designs.
     Cephalalgia. 2022;42:53-62.
     

     >> Share

     
     December 2021
241. ELIZAGARAY-GARCIA I, Carvalho GF, Szikszay TM, Adamczyk WM, et al
     Psychophysical testing in chronic migraine and chronic tension type headache: An observational study.
     Cephalalgia. 2021 Dec 7:3331024211060315. doi: 10.1177/03331024211060315.
     

     >> Share

     
     
242. OLIVEIRA AB, Mercante JPP, Peres MFP, Molina MDCB, et al
     Physical inactivity and headache disorders: Cross-sectional analysis in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
     Cephalalgia. 2021;41:1467-1485.
     

     >> Share

     
     
243. NERI I, Menichini D, Monari F, Bascio LS, et al
     Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
     Cephalalgia. 2021;41:1492-1498.
     

     >> Share

     
     November 2021
244. CHRISTENSEN SL, Rasmussen RH, Cour S, Ernstsen C, et al
     Smooth muscle ATP-sensitive potassium channels mediate migraine-relevant hypersensitivity in mouse models.
     Cephalalgia. 2021 Nov 24:3331024211053570. doi: 10.1177/03331024211053570.
     

     >> Share

     
     
245. MALEKIAN N, Bastani PB, Oveisgharan S, Nabaei G, et al
     Preventive effect of greater occipital nerve block on patients with episodic migraine: A randomized double-blind placebo-controlled clinical trial.
     Cephalalgia. 2021 Nov 17:3331024211058182. doi: 10.1177/03331024211058182.
     

     >> Share

     
     
246. CHHABRA N, Chiang CC, Di Nome MA, Houghton O, et al
     Migrainous infarction of the eye: Two cases of monocular ischemic complications associated with retinal migraine.
     Cephalalgia. 2021 Nov 17:3331024211056286. doi: 10.1177/03331024211056286.
     

     >> Share

     
     
247. NEVERDAHL JP, Uglem M, Matre D, Hansen JO, et al
     Pain thresholds and suprathreshold pain after sleep restriction in migraine - A blinded crossover study.
     Cephalalgia. 2021 Nov 17:3331024211056565. doi: 10.1177/03331024211056565.
     

     >> Share

     
     
248. TOGHA M, Martami F, Jafari E, Ariyanfar S, et al
     The prevalence and characteristics of visceral autonomic symptoms among migraineurs: A population-based study.
     Cephalalgia. 2021 Nov 17:3331024211056849. doi: 10.1177/03331024211056849.
     

     >> Share

     
     
249. REUTER U, Ehrlich M, Gendolla A, Heinze A, et al
     Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.
     Cephalalgia. 2021 Nov 7:3331024211053571. doi: 10.1177/03331024211053571.
     

     >> Share

     
     
250. PARAKRAMAWEERA R, Evans RW, Schor LI, Pearson SM, et al
     A brief diagnostic screen for cluster headache: Creation and initial validation of the Erwin Test for Cluster Headache.
     Cephalalgia. 2021;41:1298-1309.
     

     >> Share

     
     October 2021
251. HAPPOLA P, Gormley P, Nuottamo ME, Artto V, et al
     Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families.
     Cephalalgia. 2021 Oct 14:3331024211045651. doi: 10.1177/03331024211045651.
     

     >> Share

     
     
252. OVEREEM LH, Peikert A, Hofacker MD, Kamm K, et al
     Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
     Cephalalgia. 2021 Oct 13:3331024211048765. doi: 10.1177/03331024211048765.
     

     >> Share

     
     
253. MESSINA R, Rocca MA, Valsasina P, Misci P, et al
     Clinical correlates of hypothalamic functional changes in migraine patients.
     Cephalalgia. 2021 Oct 13:3331024211046618. doi: 10.1177/03331024211046618.
     

     >> Share

     
     
254. KANG L, Tang W, Zhang Y, Zhang M, et al
     The gut microbiome modulates nitroglycerin-induced migraine-related hyperalgesia in mice.
     Cephalalgia. 2021 Oct 13:3331024211050036. doi: 10.1177/03331024211050036.
     

     >> Share

     
     
255. REUTER U, Krege JH, Lombard L, Gomez Valderas E, et al
     Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
     Cephalalgia. 2021 Oct 13:3331024211048507. doi: 10.1177/03331024211048507.
     

     >> Share

     
     
256. ALPUENTE A, Gallardo VJ, Asskour L, Caronna E, et al
     Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks.
     Cephalalgia. 2021 Oct 4:3331024211040467. doi: 10.1177/03331024211040467.
     

     >> Share

     
     
257. FRANK F, Ulmer H, Sidoroff V, Broessner G, et al
     CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis.
     Cephalalgia. 2021;41.
     

     >> Share

     
     
258. TANHA HM, Martin NG, Whitfield JB, Nyholt DR, et al
     Association and genetic overlap between clinical chemistry tests and migraine.
     Cephalalgia. 2021;41.
     

     >> Share

     
     
259. GONZALEZ-QUINTANILLA V, Perez-Pereda S, Gonzalez-Suarez A, Madera J, et al
     Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: A report of two cases.
     Cephalalgia. 2021;41.
     

     >> Share

     
     
260. VAN CASTEREN DS, Verhagen IE, de Boer I, de Vries Lentsch S, et al
     E-diary use in clinical headache practice: A prospective observational study.
     Cephalalgia. 2021;41.
     

     >> Share

     
     September 2021
261. LOBO R, Wang M, Lobo S, Bahra A, et al
     Time to retire 'New daily persistent headache': Mode of onset of chronic migraine and tension-type headache.
     Cephalalgia. 2021 Sep 27:3331024211044440. doi: 10.1177/03331024211044440.
     

     >> Share

     
     
262. KIM S, Lee SB, Hong YJ, Kim Y, et al
     The influence of endogenous and exogenous hormonal factors on migraine in spontaneous postmenopausal women: A nationwide population-based study in South Korea.
     Cephalalgia. 2021 Sep 27:3331024211044441. doi: 10.1177/03331024211044441.
     

     >> Share

     
     
263. CHOWDHURY D, Bansal L, Duggal A, Datta D, et al
     TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine.
     Cephalalgia. 2021 Sep 27:3331024211047454. doi: 10.1177/03331024211047454.
     

     >> Share

     
     
264. RAFFAELLI B, Terhart M, Overeem LH, Mecklenburg J, et al
     Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study.
     Cephalalgia. 2021 Sep 27:3331024211046617. doi: 10.1177/03331024211046617.
     

     >> Share

     
     
265. INAN LE, Inan N
     Greater occipital nerve block in migraine may have a place in migraine treatment.
     Cephalalgia. 2021 Sep 23:3331024211045644. doi: 10.1177/03331024211045644.
     

     >> Share

     
     
266. BOTTIROLI S, Galli F, Ballante E, Pazzi S, et al
     Validity of the Severity of Dependence Scale for detecting dependence behaviours in chronic migraine with medication overuse.
     Cephalalgia. 2021 Sep 20:3331024211039817. doi: 10.1177/03331024211039817.
     

     >> Share

     
     
267. PUTANANICKAL N, Gross EC, Orsini AL, Schmidt S, et al
     Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: A single-centred, randomised, placebo-controlled, double-blind crossover trial.
     Cephalalgia. 2021 Sep 20:3331024211043792. doi: 10.1177/03331024211043792.
     

     >> Share

     
     
268. 
     CORRIGENDUM to 'Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis'.
     Cephalalgia. 2021 Sep 14:3331024211042798. doi: 10.1177/03331024211042798.
     

     >> Share

     
     
269. SCHWEDT TJ, Lipton RB, Ailani J, Silberstein SD, et al
     Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
     Cephalalgia. 2021 Sep 14:3331024211042385. doi: 10.1177/03331024211042385.
     

     >> Share

     
     
270. IKEGAMI D, Navratilova E, Yue X, Moutal A, et al
     A prolactin-dependent sexually dimorphic mechanism of migraine chronification.
     Cephalalgia. 2021 Sep 12:3331024211039813. doi: 10.1177/03331024211039813.
     

     >> Share

     
     August 2021
271. LIPTON RB, Dodick DW, Kudrow D, Reuter U, et al
     Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
     Cephalalgia. 2021 Aug 18:3331024211028966. doi: 10.1177/03331024211028966.
     

     >> Share

     
     
272. TFELT-HANSEN P, Jorgensen K, Diener HC
     Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks.
     Cephalalgia. 2021 Aug 18:3331024211029939. doi: 10.1177/03331024211029939.
     

     >> Share

     
     
273. CHRISTENSEN SL, Rasmussen RH, Ernstsen C, La Cour S, et al
     CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine.
     Cephalalgia. 2021 Aug 18:3331024211038884. doi: 10.1177/03331024211038884.
     

     >> Share

     
     
274. PENG KP, Schellong M, May A
     Aura in trigeminal autonomic cephalalgia is probably mediated by comorbid migraine with aura.
     Cephalalgia. 2021 Aug 18:3331024211030499. doi: 10.1177/03331024211030499.
     

     >> Share

     
     
275. GIL-GOUVEIA R, Oliveira AG
     Are PROMs passing the message? A reflection with real-life migraine patients.
     Cephalalgia. 2021 Aug 18:3331024211034509. doi: 10.1177/03331024211034509.
     

     >> Share

     
     
276. ROZEN TD, Bhatt AA
     Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention.
     Cephalalgia. 2021 Aug 18:3331024211037277. doi: 10.1177/03331024211037277.
     

     >> Share

     
     
277. BEIER D, Callesen HE, Carlsen LN, Birkefoss K, et al
     Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education in migraine treatment. A systematic review and meta-analysis.
     Cephalalgia. 2021 Aug 18:3331024211034489. doi: 10.1177/03331024211034489.
     

     >> Share

     
     
278. MARTINELLI D, Arceri S, De Icco R, Allena M, et al
     BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm.
     Cephalalgia. 2021 Aug 18:3331024211034508. doi: 10.1177/03331024211034508.
     

     >> Share

     
     
279. MCGINLEY JS, Savord A, Houts CR, Wirth RJ, et al
     What do people want to know about "Growing Up with Migraine"? Results of a preference survey of people with lived experience to guide future research.
     Cephalalgia. 2021 Aug 18:3331024211038526. doi: 10.1177/03331024211038526.
     

     >> Share

     
     
280. AL-HASSANY L, Vries T, Carpay JA, MaassenVanDenBrink A, et al
     Could erectile dysfunction be a side effect of CGRP inhibition? A case report.
     Cephalalgia. 2021 Aug 18:3331024211037304. doi: 10.1177/03331024211037304.
     

     >> Share

     
     
281. REIDY BL, Peugh J, Hershey AD, Coffey CS, et al
     Trajectory of treatment response in the child and adolescent migraine prevention (CHAMP) study: A randomized clinical trial.
     Cephalalgia. 2021 Aug 17:3331024211033551. doi: 10.1177/03331024211033551.
     

     >> Share

     
     
282. MILOSEVIC N, Trajkovic JZ, Mijajlovic M, Milosevic J, et al
     The first prevalence study of primary headaches in adults in a post-conflict area of Serbia.
     Cephalalgia. 2021;41:959-967.
     

     >> Share

     
     
283. HUTCHINSON S, Silberstein SD, Blumenfeld AM, Lipton RB, et al
     Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
     Cephalalgia. 2021;41:979-990.
     

     >> Share

     
     
284. MEHTA DG, Garza I, Robertson CE
     Two hundred and forty-eight cases of visual snow: A review of potential inciting events and contributing comorbidities.
     Cephalalgia. 2021;41:1015-1026.
     

     >> Share

     
     July 2021
285. TFELT-HANSEN P
     Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review.
     Cephalalgia. 2021 Jul 18:3331024211028959. doi: 10.1177/03331024211028959.
     

     >> Share

     
     
286. ROXAS A JR, Quiles LE, Wang SJ
     Delivery of care for migraine in the Asian Oceanian region: A cross-sectional study.
     Cephalalgia. 2021 Jul 18:3331024211024153. doi: 10.1177/03331024211024153.
     

     >> Share

     
     
287. CERAMI C, Crespi C, Bottiroli S, Santi GC, et al
     High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients.
     Cephalalgia. 2021 Jul 13:3331024211027568. doi: 10.1177/03331024211027568.
     

     >> Share

     
     
288. AKERMAN S, Salvemini D, Romero-Reyes M
     Targeting reactive nitroxidative species in preclinical models of migraine.
     Cephalalgia. 2021 Jul 13:3331024211017884. doi: 10.1177/03331024211017884.
     

     >> Share

     
     
289. DAVIDSSON OB, Olofsson IA, Kogelman LJ, Andersen MA, et al
     Twenty-five years of triptans - a nationwide population study.
     Cephalalgia. 2021;41:894-904.
     

     >> Share

     
     June 2021
290. MACKENZIE KD, Stratton JR
     Response to letter to the Editor: Assessing migraine therapeutics.
     Cephalalgia. 2021 Jun 30:3331024211021563. doi: 10.1177/03331024211021563.
     

     >> Share

     
     
291. XU C, Bussiere J
     Assessing migraine therapeutics.
     Cephalalgia. 2021 Jun 30:3331024211021569. doi: 10.1177/03331024211021569.
     

     >> Share

     
     
292. WANG SJ, Roxas AA Jr, Saravia B, Kim BK, et al
     Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
     Cephalalgia. 2021 Jun 25:3331024211024160. doi: 10.1177/03331024211024160.
     

     >> Share

     
     
293. GERSTL L, Tadych N, Heinen F, Kainz C, et al
     Migraine and the development of additional psychiatric and pain disorders in the transition from adolescence to adulthood.
     Cephalalgia. 2021 Jun 23:3331024211021792. doi: 10.1177/03331024211021792.
     

     >> Share

     
     
294. BENBOW T, Cairns BE
     Dysregulation of the peripheral glutamatergic system: A key player in migraine pathogenesis?
     Cephalalgia. 2021 Jun 20:3331024211017882. doi: 10.1177/03331024211017882.
     

     >> Share

     
     
295. FRESE A, Summ O, Evers S
     CGRP release in an experimental human trigeminal pain model.
     Cephalalgia. 2021 Jun 20:3331024211017250. doi: 10.1177/03331024211017250.
     

     >> Share

     
     
296. LENGYEL M, Hajdu D, Dobolyi A, Rosta J, et al
     TRESK background potassium channel modifies the TRPV1-mediated nociceptor excitability in sensory neurons.
     Cephalalgia. 2021;41:827-838.
     

     >> Share

     
     
297. CONSTANTINIDIS TS, Arvaniti C, Fakas N, Rudolf J, et al
     A population-based survey for disabling headaches in Greece: Prevalence, burden and treatment preferences.
     Cephalalgia. 2021;41:810-820.
     

     >> Share

     
     May 2021
298. COHEN-BARAK O, Radivojevic A, Jones A, Fiedler-Kelly J, et al
     Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach.
     Cephalalgia. 2021 May 17:3331024211007789. doi: 10.1177/03331024211007789.
     

     >> Share

     
     
299. GANTENBEIN AR, Agosti R, Gobbi C, Flugel D, et al
     Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study.
     Cephalalgia. 2021 May 17:3331024211014616. doi: 10.1177/03331024211014616.
     

     >> Share

     
     
300. TASSORELLI C, Diener HC, Silberstein SD, Dodick DW, et al
     Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine.
     Cephalalgia. 2021 May 14:3331024211010413. doi: 10.1177/03331024211010413.
     

     >> Share

     
     
301. WILKINS AJ, Haigh SM, Mahroo OA, Plant GT, et al
     Photophobia in migraine: A symptom cluster?
     Cephalalgia. 2021 May 14:3331024211014633. doi: 10.1177/03331024211014633.
     

     >> Share

     
     
302. PAZDERA L, Cohen JM, Ning X, Campos VR, et al
     Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.
     Cephalalgia. 2021 May 14:3331024211008401. doi: 10.1177/03331024211008401.
     

     >> Share

     
     
303. LIPTON RB, Burstein R, Buse DC, Dodick DW, et al
     Efficacy of erenumab in chronic migraine patients with and without ictal allodynia.
     Cephalalgia. 2021 May 13:3331024211010305. doi: 10.1177/03331024211010305.
     

     >> Share

     
     
304. 
     CORRIGENDUM to 'Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN'.
     Cephalalgia. 2021 May 5:3331024211015848. doi: 10.1177/03331024211015848.
     

     >> Share

     
     
305. DIENER HC, Ashina M, Ritter S, Paiva Da Silva Lima G, et al
     Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.
     Cephalalgia. 2021 May 3:3331024211010308. doi: 10.1177/03331024211010308.
     

     >> Share

     
     
306. YOUNG AS, Nham B, Bradshaw AP, Calic Z, et al
     Clinical, oculographic, and vestibular test characteristics of vestibular migraine.
     Cephalalgia. 2021 May 2:3331024211006042. doi: 10.1177/03331024211006042.
     

     >> Share

     
     
307. SCHWEDT TJ, Sahai-Srivastava S, Murinova N, Birlea M, et al
     Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trial.
     Cephalalgia. 2021 May 2:3331024211006903. doi: 10.1177/03331024211006903.
     

     >> Share

     
     April 2021
308. CHONG CD, Berisha V, Ross K, Kahn M, et al
     Distinguishing persistent post-traumatic headache from migraine: Classification based on clinical symptoms and brain structural MRI data.
     Cephalalgia. 2021 Apr 29:333102421991819. doi: 10.1177/0333102421991819.
     

     >> Share

     
     
309. POHL H, Benemei S, Garcia-Azorin D, Dixon J, et al
     Time lost due to an attack - a novel patient-reported outcome measure for acute migraine treatments.
     Cephalalgia. 2021 Apr 19:3331024211006048. doi: 10.1177/03331024211006048.
     

     >> Share

     
     
310. RAOOF N, Hoffmann J
     Diagnosis and treatment of idiopathic intracranial hypertension.
     Cephalalgia. 2021;41:472-478.
     

     >> Share

     
     
311. CERIANI CE, Silberstein SD
     Headache and rhinosinusitis: A review.
     Cephalalgia. 2021;41:453-463.
     

     >> Share

     
     March 2021
312. ROTHROCK JF, Diener HC
     Headache secondary to cerebrovascular disease.
     Cephalalgia. 2021 Mar 18:333102421999045. doi: 10.1177/0333102421999045.
     

     >> Share

     
     
313. ZHANG Y, Zhao X, Wang Y, Dong Z, et al
     Prevalence and characteristics of cough headache in a Chinese respiratory clinic.
     Cephalalgia. 2021;41:366-374.
     

     >> Share

     
     
314. VINOGRADOVA LV, Suleymanova EM, Medvedeva TM
     Transient loss of interhemispheric functional connectivity following unilateral cortical spreading depression in awake rats.
     Cephalalgia. 2021;41:353-365.
     

     >> Share

     
     February 2021
315. SHAH R, Assis F, Narasimhan B, Khachadourian V, et al
     Trans-nasal high-flow dehumidified air in acute migraine headaches: A randomized controlled trial.
     Cephalalgia. 2021 Feb 25:333102421997766. doi: 10.1177/0333102421997766.
     

     >> Share

     
     
316. WANG X, Yin Z, Lian Y, Xu Y, et al
     Premonitory symptoms in migraine from China: A multi-clinic study of 4821 patients.
     Cephalalgia. 2021 Feb 25:333102421997850. doi: 10.1177/0333102421997850.
     

     >> Share

     
     
317. BHAKTA M, Vuong T, Taura T, Wilson DS, et al
     Migraine therapeutics differentially modulate the CGRP pathway.
     Cephalalgia. 2021 Feb 24:333102420983282. doi: 10.1177/0333102420983282.
     

     >> Share

     
     
318. SOLLMANN N, Schandelmaier P, Weidlich D, Borner C, et al
     Patients with episodic migraine show increased T2 values of the trapezius muscles - an investigation by quantitative high-resolution magnetic resonance imaging.
     Cephalalgia. 2021 Feb 20:333102421996374. doi: 10.1177/0333102421996374.
     

     >> Share

     
     
319. SOUTHWELL J, Afridi SK
     The burden of migraine on acute and emergency services in a London teaching hospital.
     Cephalalgia. 2021 Feb 18:333102420981734. doi: 10.1177/0333102420981734.
     

     >> Share

     
     
320. DE TOMMASO M, Delussi M, Gentile E, Ricci K, et al
     Effect of single dose Erenumab on cortical responses evoked by cutaneous a-delta fibers: A pilot study in migraine patients.
     Cephalalgia. 2021 Feb 16:333102421996345. doi: 10.1177/0333102421996345.
     

     >> Share

     
     
321. DRELLIA K, Kokoti L, Deligianni CI, Papadopoulos D, et al
     Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
     Cephalalgia. 2021 Feb 10:333102421989601. doi: 10.1177/0333102421989601.
     

     >> Share

     
     
322. WIENHOLTZ NKF, Christensen CE, Zhang DG, Coskun H, et al
     Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial.
     Cephalalgia. 2021 Feb 10:333102420975395. doi: 10.1177/0333102420975395.
     

     >> Share

     
     
323. TCHIVILEVA IE, Ohrbach R, Fillingim RB, Lim PF, et al
     Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial.
     Cephalalgia. 2021 Feb 9:333102421989268. doi: 10.1177/0333102421989268.
     

     >> Share

     
     
324. ASHINA M, Reuter U, Smith T, Krikke-Workel J, et al
     Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study.
     Cephalalgia. 2021 Feb 4:333102421989232. doi: 10.1177/0333102421989232.
     

     >> Share

     
     
325. LISICKI M, Figuerola ML, Bonamico L, Lew D, et al
     The prevalence of migraine in Argentina: A reappraisal.
     Cephalalgia. 2021 Feb 1:333102421989262. doi: 10.1177/0333102421989262.
     

     >> Share

     
     
326. CHO S, Cho SJ, Lee MJ, Park JW, et al
     Clinical characteristics of pre-attack symptoms in cluster headache: A large series of Korean patients.
     Cephalalgia. 2021;41:227-236.
     

     >> Share

     
     January 2021
327. DIENER HC, Ashina M, Durand-Zaleski I, Kurth T, et al
     Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society.
     Cephalalgia. 2021 Jan 20:333102421989247. doi: 10.1177/0333102421989247.
     

     >> Share

     
     
328. CATARCI T
     Occipital ischaemic stroke after visual snow phenomenon - a case report.
     Cephalalgia. 2021 Jan 12:333102420985444. doi: 10.1177/0333102420985444.
     

     >> Share

     
     
329. VERHAGEN IE, van Casteren DS, Lentsch SV, Terwindt GM, et al
     Effect of lockdown during COVID-19 on migraine: A longitudinal cohort study.
     Cephalalgia. 2021 Jan 11:333102420981739. doi: 10.1177/0333102420981739.
     

     >> Share

     
     
330. KARSAN N, Perez-Rodriguez A, Nagaraj K, Bose PR, et al
     The migraine postdrome: Spontaneous and triggered phenotypes.
     Cephalalgia. 2021 Jan 10:333102420975401. doi: 10.1177/0333102420975401.
     

     >> Share

     
     
331. MELO-CARRILLO A, Strassman AM, Schain AJ, Adams AM, et al
     Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons.
     Cephalalgia. 2021;41:17-32.
     

     >> Share

     
     
332. LEHMAN LL, Bruccoleri R, Danehy A, Swanson J, et al
     Adverse effects of erenumab on cerebral proliferative angiopathy: A case report.
     Cephalalgia. 2021;41:122-126.
     

     >> Share

     
     December 2020
333. ILJAZI A, Ashina H, Zhuang ZA, Lopez Lopez C, et al
     Hypersensitivity to calcitonin gene-related peptide in chronic migraine.
     Cephalalgia. 2020 Dec 15:333102420981666. doi: 10.1177/0333102420981666.
     

     >> Share

     
     
334. BEGASSE DE DHAEM O, Gharedaghi MH, Bain P, Hettie G, et al
     Identification of work accommodations and interventions associated with work productivity in adults with migraine: A scoping review.
     Cephalalgia. 2020 Dec 10:333102420977852. doi: 10.1177/0333102420977852.
     

     >> Share

     
     
335. STRANG-KARLSSON S, Alenius S, Nasanen-Gilmore P, Nurhonen M, et al
     Migraine in children and adults born preterm: A nationwide register linkage study.
     Cephalalgia. 2020 Dec 9:333102420978357. doi: 10.1177/0333102420978357.
     

     >> Share

     
     
336. POZO-ROSICH P, Coppola G, Pascual J, Schwedt TJ, et al
     How does the brain change in chronic migraine? Developing disease biomarkers.
     Cephalalgia. 2020 Dec 8:333102420974359. doi: 10.1177/0333102420974359.
     

     >> Share

     
     
337. SCHRAMM S, Tenhagen I, Schmidt B, Holle-Lee D, et al
     Prevalence and risk factors of migraine and non-migraine headache in older people - results of the Heinz Nixdorf Recall study.
     Cephalalgia. 2020 Dec 3:333102420977183. doi: 10.1177/0333102420977183.
     

     >> Share

     
     
338. IRIMIA P, Martinez-Valbuena I, Minguez-Olaondo A, Dominguez-Vivero C, et al
     Interictal amylin levels in chronic migraine patients: A case-control study.
     Cephalalgia. 2020 Dec 3:333102420977106. doi: 10.1177/0333102420977106.
     

     >> Share

     
     
339. LIPTON RB, Tepper SJ, Silberstein SD, Kudrow D, et al
     Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
     Cephalalgia. 2020 Dec 3:333102420973994. doi: 10.1177/0333102420973994.
     

     >> Share

     
     
340. WOOD ME, Burch RC, Hernandez-Diaz S
     Polypharmacy and comorbidities during pregnancy in a cohort of women with migraine.
     Cephalalgia. 2020 Dec 3:333102420975394. doi: 10.1177/0333102420975394.
     

     >> Share

     
     
341. GROENKE BR, Daline IH, Nixdorf DR
     SUNCT/SUNA: Case series presenting in an orofacial pain clinic.
     Cephalalgia. 2020 Dec 3:333102420977292. doi: 10.1177/0333102420977292.
     

     >> Share

     
     November 2020
342. GOADSBY PJ, Blumenfeld AM, Lipton RB, Dodick DW, et al
     Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
     Cephalalgia. 2020 Nov 26:333102420970523. doi: 10.1177/0333102420970523.
     

     >> Share

     
     
343. GHANIZADA H, Iljazi A, Ashina H, Do TP, et al
     Nocebo response in human models of migraine: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled, two-way crossover trials in migraine without aura and healthy volunteers.
     Cephalalgia. 2020 Nov 26:333102420970489. doi: 10.1177/0333102420970489.
     

     >> Share

     
     
344. ASHINA M, Dolezil D, Bonner JH, Zhou L, et al
     A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.
     Cephalalgia. 2020 Nov 24:333102420970889. doi: 10.1177/0333102420970889.
     

     >> Share

     
     
345. VAN CASTEREN DS, Verhagen IE, Onderwater GL, MaassenVanDenBrink A, et al
     Sex differences in prevalence of migraine trigger factors: A cross-sectional study.
     Cephalalgia. 2020 Nov 17:333102420974362. doi: 10.1177/0333102420974362.
     

     >> Share

     
     
346. WANG SJ, Wu JW
     Reversion from chronic migraine to episodic migraine: A new outcome measure.
     Cephalalgia. 2020 Nov 17:333102420974004. doi: 10.1177/0333102420974004.
     

     >> Share

     
     
347. GOLLION C, Gazagnes J, Fabry V, Barbieux-Guillot M, et al
     Atrial fibrillation and migraine with aura in young adults with ischemic stroke.
     Cephalalgia. 2020 Nov 17:333102420970880. doi: 10.1177/0333102420970880.
     

     >> Share

     
     
348. CARVALHO GF, Luedtke K, Szikszay TM, Bevilaqua-Grossi D, et al
     Muscle endurance training of the neck triggers migraine attacks.
     Cephalalgia. 2020 Nov 17:333102420970184. doi: 10.1177/0333102420970184.
     

     >> Share

     
     
349. LACKOVIC J, Price TJ, Dussor G
     De novo protein synthesis is necessary for priming in preclinical models of migraine.
     Cephalalgia. 2020 Nov 17:333102420970514. doi: 10.1177/0333102420970514.
     

     >> Share

     
     
350. MASTRIA G, Mancini V, Cesare MD, Puma M, et al
     Prevalence and characteristics of Alice in Wonderland Syndrome in adult migraineurs: Perspectives from a tertiary referral headache unit.
     Cephalalgia. 2020 Nov 9:333102420968245. doi: 10.1177/0333102420968245.
     

     >> Share

     
     
351. DODICK DW, Doty EG, Aurora SK, Ruff DD, et al
     Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.
     Cephalalgia. 2020 Nov 3:333102420966658. doi: 10.1177/0333102420966658.
     

     >> Share

     
     
352. KOPRUSZINSKI CM, Thornton P, Arnold J, Newton P, et al
     Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine.
     Cephalalgia. 2020 Nov 1:333102420966581. doi: 10.1177/0333102420966581.
     

     >> Share

     
     
353. PETRUSIC I, Zidverc-Trajkovic J
     Redefining types of migraine aura.
     Cephalalgia. 2020 Nov 1:333102420970186. doi: 10.1177/0333102420970186.
     

     >> Share

     
     
354. LEVINE A, Vanderah TW, Largent-Milnes TM
     An underrepresented majority: A systematic review utilizing allodynic criteria to examine the present scarcity of discrete animal models for episodic migraine.
     Cephalalgia. 2020 Nov 1:333102420966984. doi: 10.1177/0333102420966984.
     

     >> Share

     
     October 2020
355. LINSTRA KM, Ibrahimi K, van Casteren DS, Wermer MJ, et al
     Pain perception in women with menstrually-related migraine.
     Cephalalgia. 2020 Oct 21:333102420966977. doi: 10.1177/0333102420966977.
     

     >> Share

     
     
356. ERNSTSEN C, Christensen SL, Olesen J, Kristensen DM, et al
     No additive effect of combining sumatriptan and olcegepant in the GTN mouse model of migraine.
     Cephalalgia. 2020 Oct 15:333102420963857. doi: 10.1177/0333102420963857.
     

     >> Share

     
     
357. RIST PM, Bernstein C, Kowalski M, Osypiuk K, et al
     Multimodal chiropractic care for migraine: A pilot randomized controlled trial.
     Cephalalgia. 2020 Oct 13:333102420963844. doi: 10.1177/0333102420963844.
     

     >> Share

     
     
358. ZELE AJ, Dey A, Adhikari P, Feigl B, et al
     Melanopsin hypersensitivity dominates interictal photophobia in migraine.
     Cephalalgia. 2020 Oct 12:333102420963850. doi: 10.1177/0333102420963850.
     

     >> Share

     
     
359. 
     Migraine Trust Virtual 2020 - Author index.
     Cephalalgia. 2020;40.
     

     >> Share

     
     
360. PERES MF, Evers S
     Using social media and search engine data in headache research.
     Cephalalgia. 2020;40:1274-1275.
     

     >> Share

     
     September 2020
361. ZAGAMI AS, Shaikh S, Mahns D, Lambert GA, et al
     A potential role for two brainstem nuclei in craniovascular nociception and the triggering of migraine headache.
     Cephalalgia. 2020 Sep 29:333102420960039. doi: 10.1177/0333102420960039.
     

     >> Share

     
     
362. KOPRUSZINSKI CM, Navratilova E, Swiokla J, Dodick DW, et al
     A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
     Cephalalgia. 2020 Sep 26:333102420959794. doi: 10.1177/0333102420959794.
     

     >> Share

     
     
363. SMITH JH
     Have you ever experienced a headache of any kind?
     Cephalalgia. 2020;40:1132-1133.
     

     >> Share

     
     July 2020
364. LIU Y, Wang M, Bian X, Qiu E, et al
     Proposed modified diagnostic criteria for recurrent painful ophthalmoplegic neuropathy: Five case reports and literature review.
     Cephalalgia. 2020 Jul 28:333102420944872. doi: 10.1177/0333102420944872.
     

     >> Share

     
     December 2019
365. HVEDSTRUP J, Kolding LT, Younis S, Ashina M, et al
     Ictal neck pain investigated in the interictal state - a search for the origin of pain.
     Cephalalgia. 2019 Dec 18:333102419896369. doi: 10.1177/0333102419896369.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share